Connect Biopharma (NASDAQ:CNTB) Stock Rating Reaffirmed as Buy by HC Wainwright

Connect Biopharma (NASDAQ:CNTB)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Thursday, Marketbeat Ratings reports. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.

A number of other research firms have also issued reports on CNTB. Weiss Ratings upgraded Connect Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 24th. Piper Sandler began coverage on shares of Connect Biopharma in a research note on Friday, June 26th. They issued an “overweight” rating and a $7.00 price target on the stock. Oppenheimer lowered their target price on Connect Biopharma to $5.00 and set an “outperform” rating on the stock in a research note on Tuesday, September 22nd. Wall Street Zen raised Connect Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Canaccord Genuity Group decreased their target price on shares of Connect Biopharma from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, September 16th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $6.14.

Connect Biopharma Price Performance

Shares of NASDAQ:CNTB opened at $0.94 on Thursday. The company has a current ratio of 2.37, a quick ratio of 2.37 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average is $1.83 and its two-hundred day moving average is $2.23. The firm has a market capitalization of $59.49 million, a P/E ratio of -0.79 and a beta of -0.16. Connect Biopharma has a 52 week low of $0.85 and a 52 week high of $3.82.

Connect Biopharma (NASDAQ:CNTB) last announced its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.04. The business had revenue of $2.75 million for the quarter, compared to the consensus estimate of $0.74 million. Analysts anticipate that Connect Biopharma will post -1.09 earnings per share for the current year.

Institutional Trading of Connect Biopharma

A number of institutional investors have recently modified their holdings of the company. ADAR1 Capital Management LLC acquired a new position in Connect Biopharma during the first quarter valued at approximately $1,945,000. Knott David M Jr grew its stake in shares of Connect Biopharma by 93.9% during the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after buying an additional 187,835 shares during the last quarter. Richmond Brothers Inc. bought a new stake in Connect Biopharma during the 4th quarter worth $489,000. Simplify Asset Management Inc. acquired a new stake in shares of Connect Biopharma during the first quarter valued at about $135,000. Finally, Bank of America Corp DE bought a new position in Connect Biopharma in the 1st quarter valued at approximately $41,000. 58.72% of the stock is currently owned by institutional investors.

About Connect Biopharma

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.